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Abstract Alzheimer’s disease (AD), the most prevalent form
of dementia worldwide, is a complex neurodegenerative dis-
ease characterized by the progressive loss of memory and
other cognitive functions. The pathogenesis of AD is not yet
completely understood. Although long non-coding RNAs
(lncRNAs) have recently been shown to play a role in AD
pathogenesis, the specific influences of lncRNAs in AD re-
main largely unknown; in particular, hippocampal lncRNA
expression profiles in AD rats are lacking. In this study, mi-
croarray analysis was performed to investigate the hippocam-
pal expression patterns of dysregulated lncRNAs in a rat mod-
el of AD. A total of 315 lncRNAs and 311 mRNAs were
found to be significantly dysregulated in the AD model
(≥2.0 fold, p < 0.05). Then, quantitative real-time PCR was
used to validate the expression of selected lncRNAs and
mRNAs. Bioinformatics tools and databases were employed
to explore the potential lncRNA functions. This is the first
study to comprehensively identify dysregulated hippocampal
lncRNAs in AD and to demonstrate the involvement of dif-
ferent lncRNA expression patterns in the hippocampal patho-
genesis of AD. This information will enable further research
on the pathogenesis of AD and facilitate the development of
novel AD therapeutics targeting lncRNAs.
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Introduction
Alzheimer’s disease (AD) is considered to be the most com-
mon cause of dementia; AD is a progressive neurodegenera-
tive disease characterized by the accumulation of
amyloid-β(Aβ) plaques and neurofibrillary tangles, synaptic
and neuronal loss, and cognitive decline [1]. In the USA
alone, an estimated 5.2 million individuals aged 65 and older
have AD, and this number is expected increase to 13.8 million
by 2050 [2]. Unfortunately, no currently available therapeutic
strategies for AD slow or stop the neuronal damage that
causes AD symptoms and eventually results in death [3, 4].
Thus, there is an urgent need for novel strategies of improving
our mechanistic understanding of AD, which could lead to the
discovery of novel therapeutic targets.
Long non-coding RNAs (lncRNAs), a subclass of
ncRNAs, are most commonly defined as the transcripts of
more than 200 nucleotides that structurally resemble
mRNAs but have no protein-coding capacity [5]. With the
development of techniques to detect lncRNA, accumulating
evidence indicates that lncRNAs participate in a wide variety
of important biological phenomena, such as imprinting geno-
mic loci, influencing chromosome conformation and alloste-
rically regulating enzymatic activity [6]. Moreover, multiple
lines of evidence have linked lncRNA mutations and dysreg-
ulation with diverse human diseases, ranging from different
types of cancer and neurodegeneration to gynaecological dis-
eases [7–9].
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The role of lncRNAs in AD has attracted considerable at-
tention. Recent studies have further confirmed the involve-
ment of certain lncRNAs in AD [10–13]. In addition, with
recent advancements in transcriptome-wide profiling, numer-
ous AD-associated lncRNAs have been discovered.
Furthermore, the dysregulation of lncRNA expression in
post-mortem tissue samples from AD patients [14, 15] and
transgenic AD animals [16] has been investigated. Despite
these findings, the expression patterns, targets, and functions
of lncRNAs involved in the pathogenesis of AD remain large-
ly unknown [17]. Therefore, further research is of great
importance.
In addition, as a crucial component of the medial temporal
lobe memory circuit, the hippocampus is affected early in AD
and displays synaptic and intraneuronal molecular remodel-
ling against a pathological background of extracellular Aβ
deposition and intracellular neurofibrillary tangle formation
in the early stages of AD [18]. Moreover, behavioural studies
have long suggested that the hippocampus plays a critical role
in learning and memory, which depend on functional and
structural changes occurring in the hippocampus, such as
long-term potentiation and synaptic remodelling [19].
Therefore, in the present study, we applied microarray tech-
nology to analyse the expression profiles of lncRNAs and
messenger RNAs (mRNAs) in the hippocampus of rats in a
validated AD model. Additionally, gene ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) analy-
ses were performed to predict the biological roles and poten-
tial signalling pathways of these differentially expressed
lncRNAs. Moreover, an lncRNA-mRNA network analysis
was conducted to further explore the potential roles of differ-
entially expressed lncRNAs in AD pathogenesis.
Materials and Methods
Ethics Statement
All animal protocols were approved by the Central South
University (Changsha, China) and were performed in compli-
ance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals. This investigation was con-
ducted in accordance with ethical standards and the
Declaration of Helsinki, as well as according to national and
international guidelines. This research was approved by the
authors’ institutional review board.
Animals and Experimental Design
A total of 20 adult, male Sprague–Dawley rats (250 ± 30 g)
were purchased from the Laboratory Animal Centre of Central
South University. The animals were housed under controlled
conditions (12-h light/dark cycle, 25 °C, 50 ± 10 % relative
humidity) with water and food pellets available ad libitum.
The animals were randomly divided into the following two
groups (n = 10 in each group): (1) the AD group and (2) the
control group.
Surgery
In this experiment, we utilized an intracerebroventricular
(ICV) injection of Aβ1–42 oligomers into the cerebral ventri-
cles of the animals to induce a validated AD model, as we
have previously described [20]. In brief, the animals were
anaesthetised with 10 % chloral hydrate (4 ml/kg) and placed
in a stereotactic frame. The Aβ1–42 oligomers(5 μl*2, Sigma,
St. Louis, MO, USA) were injected bilaterally into the lateral
ventricles through a stainless steel cannula by using the fol-
lowing coordinates: 1.1 mm posterior to the bregma, 2.2 mm
lateral to the sagittal suture, and 3.0 mm beneath the dura. For
the control group, the vehicle was injected bilaterally into the
lateral ventricles through a stainless steel cannula by using the
above-mentioned coordinates.
Sample Collection
After the Morris water maze test was completed, all rats were
anaesthetised with chloral hydrate and were sacrificed via de-
capitation. Their hippocampal tissues were stored in liquid
nitrogen followed by storage at −80 °C prior to analysis.
Morris Water Maze Test
Spatial learning and memory deficits were evaluated using the
Morris water maze test as we have previously described [21],
with additional modifications. In brief, the test was conducted
at 31–35 days after injury. Initial training was conducted on
days 31–34 after injury; during this period, we trained the rats
to locate a hidden, submerged platform using peripheral visual
information. The rats were introduced into a pool at one of
four entry points, and every entry point was used over the
course of a day. The rats were given 60 s to locate the platform
and were allowed to remain on the platform for 10 s before
being removed. Rats that were unable to locate the platform
within 60 s were placed on the platform for 10 s before being
removed from the pool. On the 35th day, a probe trial was
conducted, in which the platform was removed and the num-
ber of crossings over the previous platform location was re-
corded over one 60-s trial. An overhead video camera con-
nected to the ANY-maze video tracking system (Stoelting Co.,
USA) was used to record all the trials and track the move-
ments of the animals.
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RNA Extraction
Total RNAwas extracted from each hippocampal tissue sam-
ple by soaking the tissue samples in TRIzol Reagent
(Invitrogen, Grand Island, NY, USA) in accordance with the
manufacturer’s instructions. RNA quantity and quality were
measured using a Nano Drop ND-1000, and RNA integrity
was assessed by standard denaturing agarose gel
electrophoresis.
Microarray Analysis
Sample labelling and array hybridization were performed ac-
cording to the Agilent One-Colour Microarray-Based Gene
Expression Analysis protocol (Agilent Technology), with mi-
nor modifications. In brief, mRNA was purified from total
RNA after the removal of rRNA (mRNA-ONLY™
Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sam-
ple was amplified and transcribed into fluorescent cRNA
along the entire length of the transcripts without 3′ bias via a
random priming method (Arraystar Flash RNA LabellingKit,
Arraystar). The labelled cRNAs were purified using an
RNeasy Mini Kit (Qiagen). The concentration and specific
activity of the labelled cRNAs (pmol Cy3/μg cRNA) were
measured using the NanoDrop ND-1000. In all, 1 μg of each
labelled cRNA was fragmented by adding 5 μl of
10 × Blocking Agent and 1 μl of 25 × Fragmentation Buffer
and heating the mixture at 60 °C for 30 min. Then, 25 μl of
2 × GE Hybridization Buffer was added to dilute the labelled
cRNA. Subsequently, 50 μl of hybridization solution was dis-
pensed into the gasket slide, which was then assembled with
the lncRNA expression microarray slide. The slides were in-
cubated for 17 h at 65 °C in an Agilent Hybridization Oven.
The hybridized arrays were washed, fixed and scanned using
an Agilent DNA Microarray Scanner (part number G2505C).
Microarray hybridization and expression data collection were
performed by KangChen Bio-tech, Shanghai, China.
Quantitative Real-Time-PCR Validation
As previously described [22], total RNA was reverse-
transcribed into cDNA using SuperScript III Reverse
Transcriptase(Invitrogen, Grand Island, NY, USA) in accor-
dance with the manufacturer’s instructions. An Applied
Biosystems ViiA 7 Real-Time PCR System and 2 × PCR
Master Mix were used to perform quantitative real-time
(qRT)-PCR (Arraystar). The reaction conditions were as fol-
lows: incubation at 95 °C for 10 min, followed by 40 cycles of
95 °C for 10 s and 60 °C for 1 min. The relative lncRNA and
mRNA expression levels were calculated using the 2−ΔΔCt
method and were normalized to GAPDH, as an endogenous
reference transcript [23]. The specific primers for each gene
are listed in Table 1. The data represent the means of three
experiments.
GO Annotations and KEGG Pathways
GO annotations and pathway analysis were applied to inves-
tigate the roles of all differentially expressed mRNAs, as pre-
viously described [24, 25]. In brief, GO analysis was applied
to elucidate genetic regulatory networks of interest by forming
hierarchical categories according to the molecular function,
biological process, and cellular component aspects of the dif-
ferentially expressed genes (http://www.geneontology.org).
Pathway analysis was performed to explore the significant
pathways of the differentially expressed genes, according to
KEGG (http://www.genome.jp/kegg/).
Construction of Co-Expression Network
To identify interactions among the differentially expressed
lncRNAs and mRNAs, we constructed a co-expression net-
work based on a correlation analysis of the differentially
expressed lncRNAs and mRNAs [26]. The network was con-
structed according to the normalized signal intensities of spe-
cific mRNA and lncRNA expression levels. Pearson’s corre-
lation coefficients equal to or greater than 0.7 were used to
identify the lncRNAs and coding genes. Then, the lncRNA-
mRNA co-expression network was constructed using
Cytoscape software (The Cytoscape Consortium, San Diego,
CA, USA).
Statistical Analysis
All data are shown as the mean ± standard error of the mean
(SEM) and were analysed using the statistical software SPSS
version 22.0 (SPSS Inc., Chicago, IL, USA). Student’s t test
was performed for comparisons between two groups, whereas
ANOVAwas performed for repeated measures. The false dis-
covery rate was calculated to correct the p value. Differences
with p < 0.05 were considered statistically significant. Fold
change (FC) and Student’s t test were used to analyse the
statistical significance of the microarray results. FC ≥ 2 and
p < 0.05 were considered the threshold values for designating
differentially expressed lncRNAs and mRNAs.
Results
Morris Water Maze Test
Spatial learning was evaluated on days 31–34 after the rats
received an ICVAβ1–42 injection, and a probe trial for spatial
memory was conducted on day 35. As expected, rats injected
with Aβ1–42 were less able than mice in the control group to
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find the platform and learn its location by the 34th day of
training, indicating poor learning performance (Fig. 1b). In
addition, compared with animals in the control group, the
Aβ1–42-treated animals performed poorly and failed to recol-
lect the location of the submerged platform on the 35th day,
demonstrated by significantly fewer crossings over the previ-
ous platform location (Fig. 1c).
lncRNA and mRNA Expression Profiles in AD
Microarray analysis was used to assess the expression levels
of lncRNAs in AD rats relative to those in control rats. We
identified 315 significantly dysregulated lncRNAs in the AD
rats: 238 were up-regulated, while 77 were down-regulated
(≥2.0 fold, p < 0.05). The top 40 most significantly
Table 1 Primers designed for
qRT-PCR validation of candidate
lncRNAs and mRNAs






































Fig. 1 Spatial learning and memory was assessed in Morris water maze
test. a Representative images of the swim paths on day 34, showing that
rats in the control group were able to find the hidden platform more easily
than the AD rats and indicating that the rats in the AD group (31 s)
required a longer time to find the hidden platform than the rats in the
control group (15 s); these results suggested that Aβ1–42 impaired spatial
learning ability. b Escape latency. A significant difference was detected
between the control and AD groups on days 32–34 (*p < 0.05). c Probe
test. The frequency of crossing the target platform was recorded as an
indicator of spatial memory. Significant differences were observed
between the control and AD groups (*p < 0.05). d Representative
images of the frequency of crossing the target platform, showing that
rats in the control group had a crossing frequency of approximately 3
times, while that of rats in the AD group was reduced to approximately
1 time, suggesting that there was significantly better performance in the
control group compared with the AD group; n = 6 rats/group. Data are
expressed as the mean ± standard error of the mean (SEM)
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Table 2 Top 40 aberrantly expressed lncRNAs in microarray analysis
SeqID P value Fold
change
Regulation Chr Strand Relationship AD-1 AD-2 AD-3 Control-1 Control-2 Control-3
BC158567 0.01001 4.58596 Down 20 + sense_intron_
overlap
8.00638 6.43733 7.03962 9.36119 9.59565 9.11816
BC158567 0.01001 4.58596 Down 20 + sense_exon_
overlap
8.00638 6.43733 7.03962 9.36119 9.59565 9.11816
MRAK050857 0.00001 7.65238 Down 10 − others 5.53087 5.65205 5.90255 8.58667 8.61557 8.69096
MRAK033976 0.00288 5.04632 Down X − others 5.29233 6.53179 5.94278 8.28533 8.20126 8.28601
MRuc009dux 0.00330 6.00053 Down 4 + sense_intron_
overlap
6.03729 6.69110 6.14928 8.93886 9.46715 8.22693
MRuc009dux 0.00330 6.00053 Down 4 + antisense_
intron_
overlap
6.03729 6.69110 6.14928 8.93886 9.46715 8.22693
MRAK078853 0.00005 4.46748 Down 4 + sense_exon_
overlap
5.67166 5.69835 5.37772 7.81646 7.78834 7.62132
M81783 0.04499 3.88207 Down 6 − sense_exon_
overlap
6.54969 5.91603 6.06684 8.45648 6.87919 9.06737
S69385 0.00244 11.25543 Up 8 + sense_exon_
overlap
9.22457 7.80020 8.15135 4.55781 5.46104 4.67963
uc.28- 0.00002 10.74721 Up 2 + antisense_
intron_
overlap
8.27963 8.00554 7.92272 4.83231 4.62756 4.47034
MRAK081790 0.00022 10.61600 Up X − sense_intron_
overlap
11.47399 10.67374 10.76289 7.51004 7.73699 7.43908
XR_008107 0.00003 9.80265 Up X + others 9.89685 10.08962 9.80230 6.48063 6.90673 6.52189
AB072252 0.02153 9.80128 Up 1 − others 8.06770 6.20245 7.09967 4.11682 4.90890 2.46520
uc.128- 0.01416 6.99610 Up 8 + intergenic 7.46133 6.05214 6.17050 4.63293 3.73602 2.89537
uc.80- 0.02034 4.03223 Up 3 − sense_intron_
overlap
4.03512 5.57163 4.80373 3.40618 2.50436 2.46520
XR_006076 0.00058 4.22020 Up 18 − others 4.55077 4.92157 4.75323 3.02408 2.50436 2.46520
MRAK047420 0.00084 4.01561 Up 5 + sense_intron_
overlap
5.46621 6.04554 5.64582 3.90005 3.43310 3.80757
XR_006113 0.00019 4.89262 Up 3 + sense_intron_
overlap
12.79504 13.15587 12.89520 10.60371 10.91719 10.45340
XR_009079 0.00043 4.43645 Up 7 + others 8.96824 9.31937 8.92314 6.92116 7.19221 6.64916
XR_006120 0.00028 3.95666 Up 3 + intergenic 12.37788 12.39927 12.13337 10.29845 10.57616 10.08305
MRAK043605 0.00012 3.71597 Up 10 + antisense_
exon_
overlap
9.04173 9.15901 8.99951 7.05250 7.40744 7.05909
MRAK043605 0.00012 3.71597 Up 10 + antisense_
exon_
overlap
9.04173 9.15901 8.99951 7.05250 7.40744 7.05909
XR_009080 0.00018 6.67415 Up 1 − others 11.91682 12.54961 12.23871 9.43643 9.68088 9.37209
XR_009128 0.00004 6.54726 Up 16 − intergenic 9.47314 9.82283 9.57302 6.93783 7.06204 6.73645
MRAK158075 0.00013 6.21123 Up 19 + antisense_
exon_
overlap
11.63517 12.06746 11.72937 9.16909 9.39121 8.96705
MRuc007nww 0.00018 5.77962 Up 6 + intergenic 12.46794 13.04085 12.73809 10.17715 10.38814 10.08866
XR_008038 0.00008 5.72687 Up 2 − intergenic 11.56619 11.93042 11.66727 9.13306 9.41106 9.06652
XR_007242 0.00001 7.29233 Up 15 + intergenic 9.60316 9.58071 9.36365 6.59651 6.79242 6.55945
XR_008129 0.00001 7.07133 Up 16 − intergenic 8.37982 8.26123 8.10604 5.44713 5.51678 5.31723
XR_008124 0.00034 6.46782 Up 18 − others 6.60833 6.00739 5.97723 3.32404 3.46613 3.72295
XR_006337 0.00099 6.59840 Up 12 − intergenic 6.06002 5.51444 5.50684 3.15227 3.29748 2.46520
U89530 0.00040 5.56718 Up 3 − intergenic 6.49347 6.00548 5.95748 3.73959 3.89338 3.39263
MRAK044406 0.01616 4.85928 Up 2 − sense_exon_
overlap
7.99810 6.33157 6.47274 4.56294 5.03938 4.35786
uc.243+ 0.01513 3.76335 Up 2 − intergenic 9.44347 8.51668 8.32754 6.51866 7.48587 6.54710
AJ131563 0.00182 4.62465 Up 16 + 14.15639 13.39135 13.57111 11.38921 11.87005 11.23156
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Fig. 2 The heat map and hierarchical clustering of the top 40
differentially expressed lncRNAs (a) and mRNAs (b) between AD and
control hippocampal samples. The data are depicted as a data matrix, in
which each row represents one lncRNA (mRNA) and each column
represents one of the hippocampal samples. The relative lncRNA
(mRNA) expression is depicted according to the colour scale shown at
the top. Red represents high relative expression, and green represents low
relative expression; −2.0, 0 and 2.0 are FCs in the corresponding
spectrum. The magnitude of deviation from the median is represented
by the colour saturation
Table 2 (continued)
SeqID P value Fold
change
Regulation Chr Strand Relationship AD-1 AD-2 AD-3 Control-1 Control-2 Control-3
sense_exon_
overlap
DQ223059 0.00212 4.47442 Up 10 + others 12.99165 12.36331 12.52671 10.34195 10.93173 10.12288
MRAK030941 0.00135 4.04066 Up 4 + sense_exon_
overlap
15.33834 14.99113 15.12357 13.02945 13.58079 12.79903
uc.253+ 0.00427 3.70040 Up 5 + intergenic 11.93550 11.18617 11.56148 9.58592 10.12549 9.30870
uc.412+ 0.00022 3.98847 Up 10 − sense_intron_
overlap
4.76540 4.37265 4.24680 2.42778 2.50436 2.46520
XR_006990 0.00213 3.59883 Up Un + intergenic 5.02968 4.64237 4.48417 3.01448 3.13395 2.46520
SeqID: lncRNA name. P value:P value calculated from unpaired t-test. Fold Change: the absolute ratio (no log scale) of normalized intensities between
two groups(AD vs Control). Chr: chromosome no. which lncRNA is transcribed. Strand: the strand of chromosome which lncRNA is transcribed; ‘+’ is
sense strand of chromosome, ‘−’ is antisense strand of chromosome. Relationship: Bsense exon overlap^: the LncRNA’s exon is overlapping a coding
transcript exon on the same genomic strand; Bsense intron overlap^: the LncRNA is overlapping the intron of a coding transcript on the same genomic
strand; Bantisense_exon_overlap^: the LncRNA is transcribed from the antisense strand and overlapping with a coding transcript; Bantisense_intron_
overlap^: the LncRNA is transcribed from the antisense strand without sharing overlapping exons;"bidirection^: the LncRNA is oriented head to head to
a coding transcript within 1000 bp; Bintergenic^: there are no coding transcripts within 30 kb of the LncRNA; Bothers^: means other LncRNAs. AD1–
3,Control1–3:Normalized Intensity of each sample (log2 transformed)
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differentially expressed lncRNAs are shown in Table 2.
Among the dysregulated lncRNA transcripts, S69385 was
the most down-regulated, with an FC of 11.25, whereas
MRAK050857 was the most up-regulated, with an FC of
7.65. The variation of lncRNA expression between the AD
and control rats is shown with a scatter plot (Fig. 2a). The
clustering analysis revealed the relationships among lncRNA
expression patterns in different samples (Fig. 3a).
Using microarray analysis, we identified 311 significantly
dysregulated mRNAs in the AD rats: 191 were up-regulated,
while 120 were down-regulated (≥2.0 fold, p < 0.05). The top
40 most significantly differentially expressed mRNAs are
shown in Table 3. The most up-regulated and down-
regulated mRNA transcripts were Ckm(NM_012530) and
P518 (NM_198200), with an FC of 12.08 and 10.05, respec-
tively. The variation of mRNA expression between the AD
and control rats is shown with a scatter plot (Fig. 2b). The
clustering analysis revealed the relationships among mRNA
expression patterns in different samples (Fig. 3b).
Validation of the Microarray Data Using qRT-PCR
A total of six dysregulated lncRNAs and mRNAs were ran-
domly selected to validate the microarray results using qRT-
PCR. Consistent with the microarray chip data, the qRT-PCR
results demonstrated that the lncRNAs MRAK088596,
MRAK081790 and MAPK10 were up-regulated and that
BC092582, MRAK050857 and S100A8 were down-
regulated in the AD rats compared with the controls (Fig. 4).
Gene Enrichment and KEGG Pathway Analyses
To predict the functions of the lncRNAs, we employed a pre-
viously described method [27]. In brief, we first identified and
then conducted a functional enrichment analysis of the
mRNAs co-expressed with each of the differentially
expressed lncRNAs. The enriched functional terms were used
as the predicted functional terms for each given lncRNA.
As shown in Fig. 5, the GO analysis indicated that the most
enriched GO terms targeted by the mRNAs co-expressed with
lncRNAs were endocrine process (ontology: biological pro-
cess, GO:0050886), extracellular region part (ontology: cellu-
lar component, GO:0044421) and neurokinin receptor bind-
ing (ontology: molecular function, GO:0031834).
Furthermore, the KEGG pathway analysis indicated that the
mRNAs co-expressed with lncRNAs were involved in the
regulation of antigen processing and presentation, neuroactive
ligand-receptor interaction, axon guidance, and the synaptic
vesicle cycle, among others. The top 40 KEGG pathways are
listed in Fig. 6.
lncRNA-mRNA Network Analysis
As shown in Fig. 7, the whole co-expression network profile
consisted of 454 network nodes and 478 connections among
168 differentially expressed mRNAs and 286 differentially
expressed lncRNAs. There were 200 negative and 278 posi-
tive interactions within the network. Moreover, our data
showed that one mRNA may correlate with 1–66 lncRNAs
and that one lncRNA may correlate with 1–2 mRNAs.
Fig. 3 The scatter plot of lncRNA (a) and mRNA (b) expression
variation between the AD and control hippocampal samples. The values
shown on the x-axis and y-axis in the scatter plot are the normalized
signal values of each sample (log2 scale). The green lines are fold-
change lines (the default fold-change value given is 2.0). The lncRNAs
(mRNAs) above the top green line and below the bottom green line
showed an FC >2.0 in expression between the 2 compared samples
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Discussion
Analysing the expression profiles of lncRNAs may provide
new insights into our understanding of the aetiology and path-
ophysiology of AD. In previous studies, D.Y. Lee et al. exam-
ined the dysregulated expression of intergenic lncRNAs
(lincRNAs), a significant subgroup of lncRNAs, in a triple
transgenic model of AD (3xTg-AD) [16], X. Zhou et al. iden-
tified AD-associated lncRNAs based on post-mortem tissue
samples of AD patients [14]. Additionally, M. magistri et al.
identified several annotated and non-annotated lincRNAs that
are differentially expressed in the hippocampus in late-onset
Table 3 Top 40 aberrantly expressed mRNAs in microarray analysis
SeqID GeneSymbol P value Fold
change
Regulation Chr AD-1 AD-2 AD-3 Control-1 Control − 2 Control − 3
NM_131912 Kcnh7 0.00037 11.06140 Up 3 11.30127 10.61836 10.70082 7.60876 7.65469 6.95462
NM_001025134 Qpc 0.00032 10.39597 Up 10 6.37899 5.97278 6.02696 3.27530 2.50436 2.46520
NM_001013861 RGD1307851 0.00069 8.45568 Up 10 7.27314 6.97233 6.68490 4.41475 3.46865 3.80720
NM_001134623 RGD1560289 0.00132 7.65156 Up 4 7.46718 7.21876 7.13580 4.89982 4.42654 3.68811
NM_012530 Ckm 0.00006 12.08045 Up 1 10.79360 11.35903 11.15888 7.39529 7.74974 7.38268
NM_001005565 arhgef6 0.00002 8.69988 Up X 7.92966 7.82064 7.80281 4.57567 4.98291 4.63155
NM_001130510 Dnajb7 0.00009 7.37606 Up 7 12.31645 12.68693 12.35062 9.52755 9.82563 9.35227
NM_182474 LOC299282 0.03959 6.15219 Up 6 6.26476 7.15561 6.68019 4.53369 5.23837 2.46520
NM_001009650 Taar5 0.00323 3.85177 Up 1 7.59855 6.56191 7.18826 5.07491 5.14253 5.29471
NM_134377 Clstn2 0.01116 3.67028 Up 8 10.99065 12.38604 11.62870 9.79077 10.00038 9.58658
NM_001000520 Olr1346 0.00853 3.56797 Up 9 6.82078 7.98940 7.87742 5.57183 5.83954 5.77092
NM_001008815 Krt80 0.00069 5.82118 Up 7 12.52671 13.29509 12.98709 10.29545 10.68643 10.20308
NM_001000512 Olr601_predicted 0.00034 4.60897 Up 3 4.79276 4.92615 4.29177 2.42778 2.50436 2.46520
NM_019350 Syt5 0.00086 3.58122 Up 1 12.20464 12.90256 12.50704 10.63153 10.75588 10.70548
NM_001100990 Rspo3 0.00012 3.52906 Up 1 9.81657 9.94154 9.54918 7.87261 7.97046 8.00638
NM_057127 Slc26a2 0.00126 5.92500 Up 18 10.07056 10.23371 10.05481 7.40892 8.14971 7.09999
NM_012926 Cd80 0.00021 5.62333 Up 11 7.63253 7.42776 7.38456 4.64968 5.24624 5.07467
NM_001109601 Tcl1a 0.00082 6.24817 Up 6 11.46388 10.90778 11.00265 8.32631 8.94392 8.17378
NM_001130502 RGD1562089 0.00125 5.29588 Up 7 12.79245 12.27743 12.31050 9.80832 10.54440 9.81304
NM_001000627 Olr701_predicted 0.00104 3.99558 Up 3 5.37576 5.48705 5.67957 3.90762 3.48223 3.15731
NM_053677 Chek2 0.00009 4.79475 Up 12 8.86950 8.84403 8.67135 6.52976 6.75512 6.31564
NM_001108298 Cdc6 0.00004 4.32074 Up 10 6.27822 6.10731 6.20886 4.13715 4.21775 3.90566
NM_001000045 Olr1564 0.00050 4.37034 Up 11 8.59920 8.19315 8.01413 6.13911 6.33668 5.94745
NM_133554 Slc17a1 0.00021 4.07956 Up 17 9.61966 9.26160 9.35299 7.23515 7.61283 7.30103
NM_001134526 RGD1305298 0.00028 3.80143 Up 6 12.70549 12.87161 12.56917 10.78576 11.02570 10.55518
NM_001044267 MGC112775 0.00171 4.73274 Up 5 11.89504 11.26799 11.38203 9.38440 9.60196 8.83066
NM_001105892 Dscr6 0.00213 4.35798 Up 11 13.28813 12.66876 12.81105 10.74262 11.23262 10.42171
NM_001000743 Olr110_predicted 0.00148 4.29979 Up 1 8.85370 8.41559 8.83855 6.45820 7.04732 6.28952
NM_001009177 Stfa3l1 0.00395 3.52549 Up 11 10.36907 9.74567 9.85851 8.14118 8.59783 7.78076
NM_022927 Mid1 0.00299 3.42529 Up X 12.30728 11.74943 11.98512 10.15123 10.66069 9.90122
NM_198200 P518 0.00356 10.05736 Down 3 2.53407 3.09987 4.04598 7.14801 6.07090 6.45154
NM_019265 Scn11a 0.01023 6.57096 Down 8 2.53407 2.81928 2.83517 5.38697 6.48818 4.46168
NM_053744 Dlk1 0.00305 4.86921 Down 6 7.49082 8.48974 8.07381 10.28931 10.66765 9.94847
NM_173319 LOC286985 0.00018 3.94332 Down 1 2.53407 2.95543 2.97305 4.73203 4.86678 4.80198
NM_001106875 Acer1 0.02224 3.93238 Down Un 3.39316 3.63306 2.98687 5.32956 4.41967 6.19006
NM_053822 S100a8 0.02769 4.93494 Down 2 4.79954 2.68874 2.88047 5.87408 5.83380 5.56997
NM_001033075 Defa7 0.00194 3.43660 Down 16 5.59667 4.78587 5.36146 6.97259 7.13337 6.98098
NM_001101018 Oaz3 0.02678 3.46768 Down 2 5.80303 4.00098 4.82002 6.60239 6.61141 6.79215
NM_031506 Cftr 0.01607 3.90136 Down 4 4.62705 3.08700 3.48477 5.67597 5.42079 5.99400
NM_001109547 Fam101a 0.00538 3.39621 Down 12 6.88143 5.85283 6.07142 8.08245 7.88576 8.12925
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Alzheimer’s disease (LOAD) [15]. Despite these previously
reported findings, the roles of lncRNAs in AD remain largely
unknown because none of the currently available models re-
capitulate all aspects of human AD [28].
As a useful experimental animal model of AD emphasizing
the inflammatory component of the disease pathology, the
Aβ1–42 infusion model strongly complements the use of trans-
genic animal models in advancing our understanding of AD
[29]. However, comprehensive studies into the special expres-
sion patterns of lncRNAs in an Aβ1–42 infusion AD model
have not been reported. Thus, to the best of our knowledge,
this study is the first to describe hippocampal lncRNAs in an
Aβ1–42 infusion AD model and further our understanding of
lncRNAs that are associated with the pathogenesis of AD.
In the present study, we identified 315 lncRNAs and 311
mRNAs using a second-generation lncRNA microarray. Of
these, 238 lncRNAs and 191 mRNAs were found to be sig-
nificantly up-regulated in the AD rats compared with the con-
trol rats (FC ≥2.0, p < 0.05). In addition, several of the dys-
regulated lncRNAs andmRNAs, we identified were randomly
chosen for qRT-PCR validation, and the results confirmed the
microarray analysis findings to some extent. Among the dys-
regulated lncRNAs, 115 lincRNAs were found. Regarding the
previous studies mentioned above, 472 significantly dysregu-
lated mRNAs and 205 lincRNAs were identified in 3xTg-AD
mice [16], 64 significantly dysregulated lincRNAs were found
in AD patients [14], and 89 lincRNAs were found to be dif-
ferentially expressed in the hippocampus of LOAD patients
[15]. Taken together, these findings will likely lead towards a
better understanding of the function of dysregulated lncRNAs
in the neuropathogenesis of AD.
To predict the potential functions of the differentially
expressed lncRNAs identified in this study, GO and KEGG
pathway analyses were performed using the coding genes as-
sociated with the significantly differentially expressed
lncRNAs. GO analysis revealed that these lncRNAs are in-
volved in such biological processes as synaptic transmission
regulation, cholinergic regulation, central nervous system
neuron differentiation, external stimulus response processes
and endocrine processes, all of which are important in learning
and memory, as well as the development of AD. KEGG path-
way analysis indicated that the genes associated with the dys-
regulated lncRNAs in the AD group are involved in the neu-
roactive ligand-receptor interaction, the renin-angiotensin sys-
tem, axon guidance, and the PI3K-Akt, MAPK, and mTOR
signalling pathways. Among these, the PI3K-Akt, MAPK,
and mTOR signalling pathways play important roles in long-
term learning and memory, such as in neurocyte nutrition,
encoding protein synthesis regulation for memory formation
in the hippocampus, and memory production and consolida-
tion [30–32].
Furthermore, of these dysregulated lncRNAs, we identified
AJ131563 and MRAK043570, which are associated with the
insulin signalling pathway. Growing evidence suggests that
the deregulation of insulin signalling in the brain plays an
important role in the development of AD, which is involved
in numerous molecular pathogeneses, including APP overex-
pression, Aβ accumulation, tau hyperphosphorylation, neuro-
inflammation, oxidative stress promotion and synaptic failure
[33, 34]. On the other hand, the lncRNA MRAK043570 is
significantly associated with the PI3K-Akt, mTOR, FoxO
and AMPK signalling pathways, which are altered in brains
with AD [35, 36]; in addition, all these pathways are linked to
the regulation of autophagy, which is strongly regarded as one
of the major pathogenic mechanisms of AD [37, 38]. These
findings suggest that altered lncRNAs may be involved in
AD-associated signalling pathways. However, our knowledge
about the potential functions of these dysregulated lncRNAs
in the neuropathogenesis of AD remains limited. Thus, further
investigation is of great importance.
In the present study, we also employed an lncRNA-mRNA
network analysis to identify interactions between differential-
ly expressed mRNAs and differentially expressed lncRNAs,
as previously described [39, 40]. The co-expression network
reported here was constructed based on the 315 differentially
expressed lncRNAs and the 311 differentially expressed
mRNAs distinguishing the AD rats from the control rats.
Our results showed that a total of 168 lncRNAs and 286
mRNAs were included in the co-expression network, which
consisted of 454 network nodes and 478 connections. We also
found that S100a8, an mRNA, was correlated with up to 66
Fig. 4 The differential expression of lncRNAs and mRNAs was
validated by quantitative real-time PCR (qRT-PCR). The data showed
that the expression levels of the lncRNAs BC092582 and
MRAK050857 and the mRNA S100A8 were down-regulated and that
the lncRNAs MRAK088596 and MRAK081790 and the mRNA
MAPK10 were up-regulated in the hippocampal tissue samples from
AD rats relative to the control rats. The heights of the columns in the
chart represent FCs. The qRT-PCR results were consistent with the
microarray data
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lncRNAs; similarly, Np4 was correlated with 41 lncRNAs,
Mcpt9 with 27 lncRNAs, Defa with 24 lncRNAs.
Interestingly, a previous study has demonstrated that four
mRNAs (S100a8, Np4, Mcpt9, and Defa) were involved in
the neuroinflammatory responses in the frontal cortex of age-
ing female rats [41]. Because neuroinflammatory responses
have been implicated as a significant contributor to AD path-
ogenesis [42], the specific roles of these mRNAs with respect
to the neuropathology of AD deserve further investigation. In
addition, S100a8 is a ligand of the receptor for advanced
glycation end products, which is a receptor in the immuno-
globulin superfamily that also binds other ligands, including
advanced glycation end products, the high-mobility group
protein B1 (HMGB1), and Aβ. In addition, S100A8 could
modulate APP processing towards increased β-secretase ac-
tivity and the production of long, more amyloidogenic, Aβ
peptides [43].
We also found that 172 lncRNAs interacted with 5 mRNAs
that are mainly involved in the neuroactive ligand-receptor
interaction, lysosome and renin-angiotensin system signalling
pathways, which have been demonstrated to play important
roles in the pathophysiology of AD and could serve as poten-
tial therapeutic targets [44–46]. The co-expression network
suggests that the inter-regulation of lncRNAs and mRNAs is
involved in AD and warrants further study.
Although altered lncRNAs and mRNAs were identified
and their possible roles in the pathophysiology of AD were
investigated in this study, several limitations should be ac-
knowledged. First, the analysis was only performed using
the hippocampus of AD animals. Global lncRNA and
mRNA changes in the blood and cerebral spinal fluid of the
same AD model animals should be also determined in further
studies to more accurately reflect the pathophysiology of AD.
Second, the present study only predicted lncRNA functions
Fig. 5 Top 40 GO terms for the differences in co-expressed lncRNA
genes in AD animals and the controls. The GO enrichment analysis
provided a controlled vocabulary to describe the co-expressed genes of
the differentially expressed lncRNAs. The ontology covered three do-
mains: biological process, cellular component, and molecular function
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through investigating the functional significance of the
mRNAs co-expressed with the differentially expressed
lncRNAs. Third, gene expression microarrays have a limited
dynamic range and lack the ability to identify novel features,
such as splice isoforms or fusion transcripts. RNA-seq tech-
nology allows the discovery of previously inaccessible com-
plexities in the transcriptome, such as allele-specific expres-
sion and novel promoters and isoforms. However, the
resulting datasets are large and complex, and their interpreta-
tion is not straightforward [47]. Fourth, similar to previous
studies [47, 48], we also only performed the minimal number
of experiments, which may result in an underestimation of the
number of altered lncRNAs and mRNAs. Larger sample sizes
could achieve more optimal results. Additionally, further re-
search should select from 8 to 10 up-regulated and 8 to 10
down-regulated lncRNAs for microarray validation and in-
clude a larger sample size than that in the present study.
Future studies that overcome the limitations mentioned above
are merited.
In conclusion, the present study uses microarray data to
reveal for the first time that the hippocampal expression pat-
terns of lncRNAs are significantly altered in AD. In addition,
the data indicate that aberrantly expressed lncRNAs partici-
pate in several specific biological processes and are involved
in related pathways that may contribute to the pathogenesis of
AD. While these findings provide newfound information re-
garding the potential role of lncRNAs in AD, further research
is required to fully elucidate the detailed molecular mecha-
nisms underlying the action of significantly dysregulated
lncRNAs.
Fig. 6 KEGG pathways analysis. Top 40 pathways for the differences in lncRNA genes co-expressed in AD animals and the controls
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Fig. 7 lncRNA-mRNA-network analysis. Blue nodes represent dysregulated lncRNAs, yellow nodes represent dysregulated mRNAs. The red lines
between lncRNAs and mRNAs indicate a negative correlation, while the green lines indicate a positive correlation
Mol Neurobiol
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